MED Fundamental Analysis - MEDIFAST INC

Fundamental Rating

Taking everything into account, MED scores 4 out of 10 in our fundamental rating. MED was compared to 36 industry peers in the Personal Care Products industry. MED has a great financial health rating, but its profitability evaluates not so good. MED is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MED has reported negative net income.

MED had a positive operating cash flow in the past year.

MED had positive earnings in each of the past 5 years.

Each year in the past 5 years MED had a positive operating cash flow.

1.2 Ratios

The Return On Assets of MED (0.09%) is comparable to the rest of the industry.

MED has a Return On Equity of 0.12%. This is comparable to the rest of the industry: MED outperforms 55.56% of its industry peers.

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROIC	N/A

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Profit Margin value of 0.06%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

MED's Profit Margin has declined in the last couple of years.

In the last couple of years the Operating Margin of MED has declined.

The Gross Margin of MED (72.44%) is better than 75.00% of its industry peers.

In the last couple of years the Gross Margin of MED has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	0.06%
GM	72.44%

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MED does not have a ROIC to compare to the WACC, probably because it is not profitable.

MED has more shares outstanding than it did 1 year ago.

MED has less shares outstanding than it did 5 years ago.

MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 4.49 indicates that MED is not in any danger for bankruptcy at the moment.

MED's Altman-Z score of 4.49 is amongst the best of the industry. MED outperforms 83.33% of its industry peers.

MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	4.49

ROIC/WACCN/A

WACC8.66%

2.3 Liquidity

MED has a Current Ratio of 4.45. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.45, MED belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.

A Quick Ratio of 3.95 indicates that MED has no problem at all paying its short term obligations.

The Quick ratio of MED (3.95) is better than 91.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.45
Quick Ratio	3.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.60%.

MED shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.59% yearly.

The Revenue for MED has decreased by -36.29% in the past year. This is quite bad

Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.

EPS 1Y (TTM)-100.6%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

3.2 Future

MED is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -64.21% yearly.

MED is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -23.25% yearly.

EPS Next Y-146.27%

EPS Next 2Y-64.21%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

MED's Price/Free Cash Flow ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	187.39
EV/EBITDA	-16.15

4.3 Compensation for Growth

MED's earnings are expected to decrease with -64.21% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-64.21%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MED has a Yearly Dividend Yield of 9.97%, which is a nice return.

The stock price of MED dropped by -20.74% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.

Compared to an average industry Dividend Yield of 7.12, MED pays a better dividend. On top of this MED pays more dividend than 97.22% of the companies listed in the same industry.

MED's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.

		Industry Rank	Sector Rank
Dividend Yield	9.97%

5.2 History

The dividend of MED decreases each year by -53.42%.

MED has been paying a dividend for over 5 years, so it has already some track record.

Dividend Growth(5Y)-53.42%

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.

MED's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.

DP78.63%

EPS Next 2Y-64.21%

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDIFAST INC

NYSE:MED (12/2/2025, 3:55:55 PM)

11.015

+0.28 (+2.56%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)11-03 2025-11-03/amc

Earnings (Next)02-16 2026-02-16/amc

Inst Owners79.62%

Inst Owner Change7.25%

Ins Owners3.3%

Ins Owner Change5.24%

Market Cap121.05M

Revenue(TTM)429.69M

Net Income(TTM)248.00K

Analysts46.67

Price Target15.3 (38.9%)

Short Float %19.39%

Short Ratio12.11

Dividend

		Industry Rank	Sector Rank
Dividend Yield	9.97%

Yearly Dividend0.07

Dividend Growth(5Y)-53.42%

DP78.63%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)122.85%

Min EPS beat(2)46.69%

Max EPS beat(2)199.01%

EPS beat(4)4

Avg EPS beat(4)115.44%

Min EPS beat(4)46.69%

Max EPS beat(4)199.01%

EPS beat(8)6

Avg EPS beat(8)95.11%

EPS beat(12)10

Avg EPS beat(12)87.15%

EPS beat(16)13

Avg EPS beat(16)70.51%

Revenue beat(2)2

Avg Revenue beat(2)7.01%

Min Revenue beat(2)5.26%

Max Revenue beat(2)8.75%

Revenue beat(4)4

Avg Revenue beat(4)5.3%

Min Revenue beat(4)3.13%

Max Revenue beat(4)8.75%

Revenue beat(8)7

Avg Revenue beat(8)3.21%

Revenue beat(12)11

Avg Revenue beat(12)3.67%

Revenue beat(16)14

Avg Revenue beat(16)3.57%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)-82.22%

EPS NQ rev (3m)-82.22%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.28
P/FCF	187.39
P/OCF	16.83
P/B	0.56
P/tB	0.56
EV/EBITDA	-16.15

EPS(TTM)-0.01

EYN/A

EPS(NY)-1.41

Fwd EYN/A

FCF(TTM)0.06

FCFY0.53%

OCF(TTM)0.65

OCFY5.94%

SpS39.1

BVpS19.54

TBVpS19.54

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	0.09%
ROE	0.12%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	0.06%
GM	72.44%
FCFM	0.15%

ROA(3y)26.08%

ROA(5y)31.33%

ROE(3y)47.66%

ROE(5y)57.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)57.45%

ROCE(5y)70.54%

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-38.9%

OM growth 5Y-24.01%

PM growth 3Y-68.15%

PM growth 5Y-49.83%

GM growth 3Y-0.04%

GM growth 5Y-0.38%

F-Score5

Asset Turnover1.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	46.9%
Cap/Sales	1.52%
Interest Coverage	N/A
Cash Conversion	89.73%
Profit Quality	260.48%
Current Ratio	4.45
Quick Ratio	3.95
Altman-Z	4.49

F-Score5

WACC8.66%

ROIC/WACCN/A

Cap/Depr(3y)86.65%

Cap/Depr(5y)168.74%

Cap/Sales(3y)0.96%

Cap/Sales(5y)1.15%

Profit Quality(3y)359.98%

Profit Quality(5y)250.42%

High Growth Momentum

Growth

EPS 1Y (TTM)-100.6%

EPS 3Y-47.33%

EPS 5Y-20.59%

EPS Q2Q%-160%

EPS Next Y-146.27%

EPS Next 2Y-64.21%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-36.29%

Revenue growth 3Y-26.64%

Revenue growth 5Y-3.33%

Sales Q2Q%-36.21%

Revenue Next Year-36.56%

Revenue Next 2Y-23.25%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-120.14%

EBIT growth 3Y-55.18%

EBIT growth 5Y-26.54%

EBIT Next Year-105.07%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-99.63%

FCF growth 3Y-34.4%

FCF growth 5Y-25.51%

OCF growth 1Y-96.19%

OCF growth 3Y-36.26%

OCF growth 5Y-21.91%

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.

What is the valuation status for MED stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.

What is the profitability of MED stock?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.

Can you provide the expected EPS growth for MED stock?

The Earnings per Share (EPS) of MEDIFAST INC (MED) is expected to decline by -146.27% in the next year.

MEDIFAST INC (MED) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

What is the valuation status for MED stock?

What is the profitability of MED stock?

Can you provide the expected EPS growth for MED stock?